# COVID-19 Antigen Rapid Test Evaluation in Low-Prevalence Setting

> **NCT05911074** · — · COMPLETED · sponsor: **Foundation for Innovative New Diagnostics, Switzerland** · enrollment: 7274 (actual)

## Conditions studied

- Corona Virus Infection

## Interventions

- **DIAGNOSTIC_TEST:** The Abbott Panbio™ COVID-19 Ag Rapid Test

## Key facts

- **NCT ID:** NCT05911074
- **Lead sponsor:** Foundation for Innovative New Diagnostics, Switzerland
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-01
- **Primary completion:** 2023-03-31
- **Final completion:** 2023-03-31
- **Target enrollment:** 7274 (ACTUAL)
- **Last updated:** 2023-10-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05911074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05911074, "COVID-19 Antigen Rapid Test Evaluation in Low-Prevalence Setting". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05911074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*